Skip to content
TrialScanner

NCT07905183

A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs

Phase 3RecruitingELVNLead

Registry record

Lead sponsor
Enliven Therapeutics
Conditions
Chronic Myeloid Leukemia (CML); Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML
Primary completion
Dec 31, 2028Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT07905183 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

1 change recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.